TNF, tumor necrosis factor, 7124

N. diseases: 2724; N. variants: 31
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.400 Biomarker disease BEFREE Psoriasis Associated with Tumor Necrosis Factor-Alpha Inhibitors in Children with Inflammatory Diseases. 31646743 2019
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.400 Biomarker disease BEFREE High concentrations of tumor necrosis factor-alpha (TNFα) are found in the skin lesions and plasma of patients with psoriasis. 28272075 2019
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.400 Biomarker disease BEFREE These medications target various cytokines responsible for psoriasis manifestations such as tumor necrosis factor (TNF-α), interleukin-12, interleukin-23, and interleukin-17. 30037762 2019
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.400 Biomarker disease BEFREE Tumor necrosis factor α inhibitors may be the drug of choice in patients with both psoriasis and sickle cell disease. 30893386 2019
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.400 Biomarker disease BEFREE Tumor necrosis factor-α inhibitor-induced psoriasis in juvenile idiopathic arthritis patients. 31240749 2019
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.400 Biomarker disease BEFREE Th1, Th17, and Treg Responses are Differently Modulated by TNF-α Inhibitors and Methotrexate in Psoriasis Patients. 31101850 2019
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.400 GeneticVariation disease BEFREE TNF-α -238 G/A, -308 G/A and -857 C/T polymorphisms could be used to identity individuals with elevated susceptibility to psoriasis in certain populations. 31775137 2019
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.400 Biomarker disease BEFREE Adalimumab (ADA) is one of the tumor necrosis factor (TNF)-α monoclonal antibodies used for the treatment of psoriasis. 30672612 2019
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.400 Biomarker disease BEFREE The pro-inflammatory cytokine, TNF-α, which plays a major role in the development and persistence of diseases such as Crohn's disease, psoriasis, psoriatic arthritis, and rheumatoid arthritis, is the basis for the use of anti-TNF-α therapies. 31089365 2019
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.400 Biomarker disease BEFREE Tumor necrosis factor (TNF) inhibitors account for a large proportion of drugs used to treat psoriasis and are indicated first-line options in certain settings. 31094242 2019
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.400 AlteredExpression disease BEFREE In PS, there are enhanced type I interferon (IFN), angiogenesis, and over-expression of several proinflammatory cytokines, such as tumor necrosis factor and interleukin (IL)-1 family members generated by several immune cells including MCs. 31012218 2019
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.400 Biomarker disease BEFREE On the other hand, inhibition of IL-12-IL-23, as compared with inhibition of TNF, has greater efficacy for psoriasis, comparable efficacy for peripheral arthritis, but was ineffective in studies of axial spondyloarthritis. 31485004 2019
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.400 Biomarker disease BEFREE Biologic therapies targeting tumor necrosis factor have revolutionized treatment of immune-mediated inflammatory diseases such as psoriasis, but optimal dosing and appropriate use of therapeutic drug monitoring are not yet fully understood.Wilkinson et al. explore these questions in a real-world psoriasis cohort on adalimumab monotherapy, defining a therapeutic range and finding value in early measurement for predicting clinical response. 30579425 2019
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.400 GeneticVariation disease BEFREE Tumor necrosis factor inhibitors decrease the risk of cardiovascular events in moderate to severe psoriasis, but the association between their effects on endothelial function and those on skin lesions has not been well studied. 30168849 2019
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.400 Biomarker disease BEFREE A significant increase in PASI 75 (RR: 11.65; 95% CI: 9.01-15.06), PASI 90 (RR: 21.74; 95% CI: 14.28-33.10), PASI 100 (RR: 31.56; 95% CI: 14.66-67.96), PGA 0/1 (OR: 23.21; 95% CI: 14.61-36.89), and DLQI 0/1 (RR: 10.29; 95% CI: 7.52-14.09) was identified for anti-IL-23p19 mAb vs. placebo, and PASI 75 (RR: 1.25; 95% CI: 1.18-1.32), PASI 90 (OR: 2.56; 95% CI: 2.13-3.09), PASI 100 (OR: 2.38, 95% CI: 1.89-2.99), and DLQI 0/1 (RR: 1.33; 95% CI: 1.20-1.47) vs. tumour necrosis factor (TNF) antagonists for the treatment of psoriasis. 31389789 2019
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.400 Biomarker disease BEFREE Over the last decades, research advances in understanding the role of tumor necrosis factor alpha (TNF α) and other cytokines in the pathogenesis of psoriasis have driven the introduction of biologic agents targeting specific immune mediators in everyday clinical practice. 31623470 2019
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.400 Biomarker disease BEFREE Beside TNF-α or IL-23, the IL-17 family is a newer group that has proven implications in the pathogenesis of psoriasis. 31384317 2019
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.400 Biomarker disease BEFREE <b>Conclusions:</b> In a long-term real-life setting, drug survival of UST is better than that of TNF-a inhibitors for both biologic-naive and biologic-experienced patients with psoriasis. 29848153 2019
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.400 Biomarker disease BEFREE Anti-TNF- αtreatment-related pathways and biomarkers revealed by transcriptome analysis in Chinese psoriasis patients. 30953507 2019
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.400 Biomarker disease BEFREE TNF-α is a key cytokine for both hepatitis C progression and psoriasis. 30398009 2018
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.400 Biomarker disease BEFREE Targeting the TNFα pathway is a validated approach to the treatment of psoriasis. 28818461 2018
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.400 AlteredExpression disease BEFREE Blocking of CXCL16 expression by effective treatment of psoriasis patients with tumor necrosis factor-α blockers further supported the pathogenic role of this chemokine. 28942364 2018
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.400 AlteredExpression disease BEFREE Tumor necrosis factor α (TNFα) is a proinflammatory cytokine, and elevated levels of TNFα in serum are associated with various autoimmune diseases, including rheumatoid arthritis (RA), ankylosing spondylitis (AS), Crohn's disease (CD), psoriasis, and systemic lupus erythaematosus. 29575262 2018
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.400 Biomarker disease BEFREE T helper (Th) cytokines in psoriasis upregulate keratin (K)17, which modulates TNF-α transduction, leading to vascular adhesion molecule upregulation and lymphocytic extravasation. 28940220 2018
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.400 Biomarker disease BEFREE To determine the incidence of LTBI and active tuberculosis in patients with psoriasis receiving TNF inhibitor therapy. 29455561 2018